KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Return on Sales (2016 - 2025)

Neogenomics (NEO) has disclosed Return on Sales for 16 consecutive years, with 0.05% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 4.0% year-over-year to 0.05%, compared with a TTM value of 0.15% through Dec 2025, down 3.0%, and an annual FY2025 reading of 0.15%, down 3.0% over the prior year.
  • Return on Sales was 0.05% for Q4 2025 at Neogenomics, up from 0.14% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.62% in Q2 2021 and bottomed at 0.42% in Q1 2022.
  • Average Return on Sales over 5 years is 0.15%, with a median of 0.16% recorded in 2022.
  • The sharpest move saw Return on Sales soared 70bps in 2021, then plummeted -91bps in 2022.
  • Year by year, Return on Sales stood at 0.33% in 2021, then soared by 51bps to 0.16% in 2022, then soared by 44bps to 0.09% in 2023, then grew by 3bps to 0.09% in 2024, then soared by 42bps to 0.05% in 2025.
  • Business Quant data shows Return on Sales for NEO at 0.05% in Q4 2025, 0.14% in Q3 2025, and 0.25% in Q2 2025.